DMAC
Price
$5.42
Change
-$0.89 (-14.10%)
Updated
Nov 13 closing price
Capitalization
282.26M
137 days until earnings call
Intraday BUY SELL Signals
DNA
Price
$8.00
Change
-$0.36 (-4.31%)
Updated
Nov 13 closing price
Capitalization
484.72M
Intraday BUY SELL Signals
Interact to see
Advertisement

DMAC vs DNA

Header iconDMAC vs DNA Comparison
Open Charts DMAC vs DNABanner chart's image
DiaMedica Therapeutics
Price$5.42
Change-$0.89 (-14.10%)
Volume$766.68K
Capitalization282.26M
Ginkgo Bioworks Holdings
Price$8.00
Change-$0.36 (-4.31%)
Volume$1.49M
Capitalization484.72M
DMAC vs DNA Comparison Chart in %
DMAC
Daily Signal:
Gain/Loss:
DNA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DMAC vs. DNA commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Buy and DNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (DMAC: $5.42 vs. DNA: $8.00)
Brand notoriety: DMAC and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 240% vs. DNA: 96%
Market capitalization -- DMAC: $282.26M vs. DNA: $484.72M
DMAC [@Biotechnology] is valued at $282.26M. DNA’s [@Biotechnology] market capitalization is $484.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both DMAC and DNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 4 TA indicator(s) are bullish while DNA’s TA Score has 4 bullish TA indicator(s).

  • DMAC’s TA Score: 4 bullish, 5 bearish.
  • DNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than DNA.

Price Growth

DMAC (@Biotechnology) experienced а -12.86% price change this week, while DNA (@Biotechnology) price change was -29.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

DMAC is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($485M) has a higher market cap than DMAC($282M). DMAC YTD gains are higher at: 16.206 vs. DNA (-14.868). DMAC has higher annual earnings (EBITDA): -31.42M vs. DNA (-292.97M). DNA has more cash in the bank: 474M vs. DMAC (30M). DMAC has less debt than DNA: DMAC (292K) vs DNA (429M). DNA has higher revenues than DMAC: DNA (231M) vs DMAC (0).
DMACDNADMAC / DNA
Capitalization282M485M58%
EBITDA-31.42M-292.97M11%
Gain YTD16.206-14.868-109%
P/E RatioN/AN/A-
Revenue0231M-
Total Cash30M474M6%
Total Debt292K429M0%
FUNDAMENTALS RATINGS
DMAC: Fundamental Ratings
DMAC
OUTLOOK RATING
1..100
64
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
PROFIT vs RISK RATING
1..100
84
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DMACDNA
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 21 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
DMAC
Daily Signal:
Gain/Loss:
DNA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PXWGX26.830.14
+0.52%
Impax US Sustainable Economy Investor
JDIBX17.740.08
+0.45%
JHancock Disciplined Value Intl A
NMFAX17.050.02
+0.12%
Nationwide BNY Mellon Dyn US Core A
RBCRX13.11-0.03
-0.23%
RBC China Equity R6
VRSCX25.57-0.08
-0.31%
Voya SmallCap Opportunities Port R6

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
-1.25%
WHWK - DMAC
41%
Loosely correlated
N/A
EDIT - DMAC
33%
Loosely correlated
+1.50%
CDXS - DMAC
33%
Poorly correlated
+7.22%
XOMA - DMAC
33%
Poorly correlated
-2.52%
DNA - DMAC
32%
Poorly correlated
-1.18%
More

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-1.18%
VCYT - DNA
58%
Loosely correlated
-0.84%
RXRX - DNA
54%
Loosely correlated
-1.27%
ABCL - DNA
52%
Loosely correlated
-1.00%
ABSI - DNA
51%
Loosely correlated
-1.45%
CRSP - DNA
49%
Loosely correlated
-5.47%
More